FDA Approved: FLOLAN — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for FLOLAN (epoprostenol sodium) submitted by GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• FLOLAN (EPOPROSTENOL SODIUM)

Snippet

SUPPL AP for FLOLAN (EPOPROSTENOL SODIUM)